Prothrombin complex concentrates (PCCs) are highly purified concentrate prepared from blood plasma with hemostatic activity contain four vitamin K-dependent clotting factors (F) (II (prothrombin), VII, IX and X), for replacement therapy in patients with congenital or acquired deficiencies.
Moreover, in several European countries, prothrombin complex concentrates are also used in the management of massive peri- and postoperative bleeding.
Market Dynamics
Global Prothrombin Complex Concentrates Market is expected to show significant growth, owing to increasing approval of product. For instance, in 2013, the U.S Food and Drug Administration (FDA) accepted Octapharma USA’s Biological License Application (BLA) for octaplex 4-Factor PCC, for indication of reversal of anticoagulation therapy in patients undergoing vitamin K antagonist therapy with the need for urgent surgery or invasive procedures
Key features of the study
- This report provides in-depth analysis of the global prothrombin complex concentrates market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global prothrombin complex concentrates market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Octapharma AG, Nihon Pharmaceutical Co Ltd, Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global prothrombin complex concentrates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prothrombin complex concentrates market
Market Segmentation
- By Type (Revenue, USD Mn, 2021-2033)
- 3-Factor PCC
- 4-Factor PCC
- By Application (Revenue, USD Mn, 2021-2033)
- Acquired Coagulation Factor Deficiency
- Congenital Coagulation Factor Deficiency
- Others
- By End User (Revenue, USD Mn, 2021-2033)
- Hospital
- Ambulatory Surgical Centres
- Others
- By Region (Revenue, USD Mn, 2021-2033)
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Octapharma AG
- Nihon Pharmaceutical Co. Ltd.
- Grifols S.A.
- CSL Behring GmbH
- Kedrion Biopharma Inc.
- Shire Plc
- China Biologic Products Holdings, Inc.
- Sanquin
